- Double Mastectomy May Offer No Survival Benefit to Women With Breast Cancer
- Toxic Lead Found in Cinnamon Product, FDA Says
- Certain Abbott Blood Sugar Monitors May Give Incorrect Readings
- Athletes Can Expect High Ozone, Pollen Counts for Paris Olympics
- Fake Oxycontin Pills Widespread and Potentially Deadly: Report
- Shingles Vaccine Could Lower Dementia Risk
- Your Odds for Accidental Gun Death Rise Greatly in Certain States
- Kids From Poorer Families Less Likely to Survive Cancer
- Tough Workouts Won’t Trigger Cardiac Arrest in Folks With Long QT Syndrome
- At-Home Colon Cancer Test Can Save Lives
Orbactiv Approved for Drug-Resistant Skin Infections
![](https://ladylively.com/wp-content/uploads/2013/08/skin-care5-300x336.jpg)
The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.
The drug is sanctioned to treat methicillin-resistant Staphylococcus aureus (MRSA) and other acute bacterial skin infections. It’s the third such drug approved in 2014, following May approval of Dalvance (dalbavancin) and June approval of Sivextro (tedizolid), the FDA said.
Orbactiv’s safety and effectiveness were evaluated in two clinical studies involving almost 2,000 adults. The most common side effects included headache, nausea, vomiting, skin abscesses on the arms and legs, and diarrhea.
The drug’s label will include a boxed warning that it could interact with the blood-thinning medication warfarin, the agency said.
Orbactiv is marketed by The Medicines Company, based in Parsippany, N.J.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.